Early Data Show Biomarker Reductions, Good Safety for ABX1100 in Late-Onset Pompe Disease ABX1100 administration led to sustained knockdown of GYS1 mRNA in muscle tissue and reductions in late-onset Pompe disease biomarkers.

@arobiotx.bsky.social announced positive interim results from a phase 1b study of #ABX1100 for the treatment of late-onset #PompeDisease.

Read more: https://bit.ly/3ZnOYcb

#RareDisease #LateOnsetPompeDisease #MedSky